

FETAL *IN VIVO* CONTINUOUS CARDIOVASCULAR FUNCTION DURING CHRONIC HYPOXIA

B J Allison¹, K L Brain¹, Y Niu¹, A D Kane¹, E A Herrera², A S Thakor^{1,3}, K J Botting¹

C M Cross¹, N Itani¹, K L Skeffington¹, C Beck¹ & D A Giussani¹

¹Department of Physiology, Development & Neuroscience, University of Cambridge, Downing Street,
Cambridge, CB2 3EG, UK

²Laboratorio de Función y Reactividad Vascular, Programa de Fisiopatología, Instituto de Ciencias
Biomédicas, Facultad de Medicina, Universidad de Chile Santiago, Chile

³Department of Radiology, Stanford University Medical Center, Palo Alto, CA, 94305, USA

Journal: *The Journal of Physiology*

Section: Techniques for Physiology

Subject area: Cardiovascular

Running title: Fetal brain sparing during chronic hypoxia

Key words: Cerebral blood flow, femoral blood flow, oxygen delivery, glucose delivery,
placental insufficiency, preeclampsia

Correspondence: Prof. Dino A Giussani, PhD
Department of Physiology, Development & Neuroscience
University of Cambridge
CB2 3EG
Tel: +44 1223 333894
Fax: +44 1223 333840
E-mail: dag26@cam.ac.uk

Key points

- The *in vivo* fetal cardiovascular defence to chronic hypoxia has remained by and large an enigma because no technology has been available to induce significant and prolonged fetal hypoxia whilst recording longitudinal changes in fetal regional blood flow as the hypoxic pregnancy is developing;
- We introduce a new technique able to maintain chronically instrumented maternal and fetal sheep preparations under isobaric chronic hypoxia for most of gestation, beyond levels that can be achieved by high altitude and of relevance in magnitude to the human IUGR fetus;
- This technology permits wireless recording in free-moving animals of longitudinal maternal and fetal cardiovascular function, including beat-to-beat alterations in pressure and blood flow signals in regional circulations;
- The relevance and utility of the technique is presented by testing the hypotheses that the fetal circulatory brain sparing response persists during chronic fetal hypoxia and that an increase in ROS in the fetal circulation is an involved mechanism.

Abstract

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Although the fetal cardiovascular defence to acute hypoxia and the physiology underlying it have been established for decades, how the fetal cardiovascular system responds to chronic hypoxia has been comparatively understudied. We designed and created isobaric hypoxic chambers able to maintain pregnant sheep for prolonged periods of gestation under controlled significant (10% O₂) hypoxia, yielding fetal mean PaO₂ levels (11.5±0.6 mmHg) similar to those measured in human fetuses of hypoxic pregnancy. We also created a wireless data acquisition system able to record fetal blood flow signals in addition to fetal blood pressure and heart rate from free moving ewes as the hypoxic pregnancy is developing. We determined *in vivo* longitudinal changes in fetal cardiovascular function including parallel measurement of fetal carotid and femoral blood flow and oxygen and glucose delivery during the last third of gestation. The ratio of oxygen (from 2.7±0.2 to 3.8±0.8; P<0.05) and of glucose (from 2.3±0.1 to 3.3±0.6; P<0.05) delivery to the fetal carotid, relative to the fetal femoral circulation increased during and shortly after the period of chronic hypoxia. In contrast, oxygen and glucose delivery remained unchanged from baseline in normoxic fetuses. Fetal plasma urate concentration increased significantly during chronic hypoxia but not during normoxia (Δ : 4.8±1.6 vs. 0.5±1.4 $\mu\text{mol.L}^{-1}$, P<0.05). The data support the hypotheses tested and show persisting redistribution of substrate delivery away from peripheral and towards essential circulations in the chronically hypoxic fetus, associated with increases in xanthine oxidase-derived ROS.

Abbreviations: ROS, reactive oxygen species; XO, xanthine oxidase; IUGR, intrauterine growth restriction; •O₂⁻, superoxide anion; NO, nitric oxide.

Introduction

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

The phrase ‘Everest *in utero*’ was coined by Sir Joseph Barcroft to highlight that the fetus develops under conditions of relative hypoxia compared with the oxygenation of the adult individual (Barcroft *et al.* 1933). Low oxygen tension in fetal life is essential for normal placental development as well as appropriate formation and maturation of the fetal cardiovascular system (Compernelle *et al.* 2003; Burton, 2009). However, reductions in fetal oxygenation below baseline can be harmful to the developing fetus unless appropriate compensatory responses are triggered. Short term, acute episodes of fetal hypoxia are common in late gestation, such as those occurring during transient compression of the umbilical cord (Giussani *et al.* 1997) or those resulting from myometrial contractions during labour and delivery (Huch *et al.* 1977). A sustained reduction from baseline in fetal oxygenation or chronic fetal hypoxia is associated with conditions of increased placental vascular resistance, leading to impaired uteroplacental blood flow. Chronic fetal hypoxia is therefore associated with preeclampsia (Kingdom & Kaufmann, 1997), placental insufficiency (Pardi *et al.* 1993), chorioamnionitis (Maberry *et al.* 1990), gestational diabetes (Escobar *et al.* 2013) and even maternal obesity (Hayes *et al.* 2012; Kaplan-Sturk, 2013). Chronic fetal hypoxia may also occur during impaired maternal oxygenation, as in maternal smoking (Longo, 1976), maternal respiratory diseases (Katz & Scheiner, 2008), maternal severe anaemia (Davis *et al.* 2005) or pregnancy at high altitude (Makowski *et al.* 1968; Giussani *et al.* 2001; Tissot van Patot *et al.* 2012; Soria *et al.* 2013). Acute episodes of severe fetal hypoxia may result in marked fetal acidosis and cardiovascular compromise with subsequent hypoxic-ischaemic encephalopathy, which is predictive of developing cerebral palsy and cognitive disability later in life (Low *et al.* 1985; Gunn & Bennet, 2009). Chronic fetal hypoxia can lead to fetal growth restriction, compromise the development of key organs and systems and trigger an increased susceptibility to disease in later life (see Giussani & Davidge, 2013 for review). Therefore, the fetal defence responses to acute and chronic hypoxia are essential to protect against significant morbidity and mortality in the offspring. Not surprisingly, the elucidation of the fetal compensatory responses to acute and chronic hypoxia and the mechanisms mediating them remains at the forefront of perinatal science and obstetric practice today.

69 The sheep fetus has long been the experimental model of choice for investigating fetal hypoxia *in*
70 *vivo*. The fetal defence to acute hypoxia is contingent on the fetal cardiovascular system (Rudolph,
71 1984; Giussani *et al.* 1994). The fetal cardiovascular defence to acute hypoxia and the physiology
72 underlying it is well established and characterised (see Giussani, 2015 for review). In response to
73 acute hypoxia, the fetus elicits bradycardia and redistributes its cardiac output (Cohn *et al.* 1974).
74 Parallel measurement of continuous changes in carotid and femoral blood flow show cerebral
75 vasodilatation and peripheral vasoconstriction, demonstrating *in vivo* the haemodynamics of the fetal
76 brain sparing effect (Giussani *et al.* 1993). The bradycardia and peripheral vasoconstriction are
77 triggered exclusively by a carotid chemoreflex (Giussani *et al.* 1993; Bartelds *et al.* 1993). The
78 peripheral vasoconstriction is then maintained by the release of constrictor hormones into the fetal
79 circulation (Jones & Robinson, 1975; Fletcher *et al.* 2006) as well as alterations in local factors,
80 including the generation of reactive oxygen species (Thakor *et al.* 2010; 2015; Kane *et al.* 2012;
81 2014). Therefore, the physiology underlying the fetal cardiovascular defence to acute episodes of
82 hypoxia involves carotid chemoreflex and endocrine components as well as a local oxidant tone acting
83 at the level of the fetal vasculature (see Giussani, 2015).

84

85 In marked contrast, the fetal *in vivo* haemodynamic responses to chronic fetal hypoxia and the
86 mechanisms mediating them are not well characterised or understood. Progress in this field has been
87 hampered in part by the inability to record continuous cardiovascular function in the fetus, including
88 measurement of regional blood flow, as the chronic fetal hypoxia is actually occurring. Therefore, the
89 objectives of this work were to introduce to the field a new technique for physiological research and to
90 show the utility of the technique by investigating the fetal *in vivo* haemodynamic responses to
91 significant chronic hypoxia in real time. We aimed to design and create isobaric hypoxic chambers
92 able to maintain pregnant sheep for prolonged periods of gestation under controlled long-term
93 hypoxia, yielding fetal PaO₂ levels similar to those measured in human IUGR pregnancy. Our second
94 aim was to establish a wireless data acquisition system able to record fetal blood flow signals in
95 addition to fetal blood pressure and fetal heart rate from free moving ewes as the hypoxic pregnancy
96 was developing. Third, to use this system to determine *in vivo* in real time fetal cardiovascular

97 function including parallel measurement of fetal carotid and femoral blood flow and regional oxygen
98 and glucose delivery during long-term significant hypoxia in late gestation fetal sheep. We propose
99 that alterations in the fetal vascular oxidant tone contribute to the fetal redistribution of blood flow
100 away from the periphery during chronic fetal hypoxia. Therefore, the fourth aim of this work was to
101 test the inter-related hypotheses that the fetal circulatory brain sparing response does persist during
102 significant chronic fetal hypoxia and that an increase in ROS in the fetal circulation is an involved
103 mechanism. *In vivo* generation of ROS in the maternal and the fetal circulation was determined by
104 measurement of changes in plasma urate and ascorbate concentrations, two of the few accepted
105 biomarkers of ROS generation within the circulation *in vivo* (Halliwell & Gutteridge, 2004).

106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133

Methods

Ethical approval

All procedures were performed under the UK Animals (Scientific Procedures) Act 1986 and were approved by the Ethical Review Committee of the University of Cambridge.

Surgical preparation, Connection to CamDAS and Post-operative care

Twelve Welsh Mountain pregnant ewes and their singleton fetuses were surgically instrumented using strict aseptic techniques at 116 ± 1 days of gestational age (term is *ca.* 145 days), as described in detail (Fletcher *et al.* 2000; 2006). In brief, food but not water was withheld from the pregnant ewe for 24 h prior to surgery. On the day of surgery, the ewe was transferred to the preoperative room, where the neck fleece was clipped and anaesthesia was induced by injection of Alfaxan (1.5-2.5 mg.kg⁻¹ alfaxalone; Jurox Ltd, Worcestershire, UK) into the jugular vein. The ewe was then placed on her back and intubated (Portex© cuffed endotracheal tube; Smiths Medical International Ltd., Kent, UK) with the aid of a laryngoscope. Pre-operative anaesthesia was maintained by spontaneous inhalation of 1.5% isoflurane in O₂ (2 L.min⁻¹; IsoFlo©; Abbott laboratories Ltd., Berkshire, UK) and the abdomen, flanks and medial surfaces of the hind limbs were shaved and cleaned.

The ewe was then transferred to the surgical suite operating table and the shaved and cleaned surfaces were scrubbed with alcohol in water, followed by a spray of hibitane solution (Hibitane Plus© in alcohol and water; 5% chlorohexidine gluconate; Regent Medical Ltd., Manchester, UK) and another spray of concentrated iodine solution (Povidone-Iodine; Seton Healthcare Group PLC, Oldham, UK). General anaesthesia (1.5-2.0% isoflurane in 60:40 O₂:N₂O) was maintained using positive pressure ventilation in a non-rebreathing circuit (Datex-Ohmeda Ltd, Hatfield, Hertfordshire, UK). Antibiotics (30 mg.kg⁻¹ I.M. procaine benzylpenicillin; Depocillin; Intervet UK Ltd, Milton Keynes, UK) and an analgesic agent (1.4 mg.kg⁻¹ S.C. carprofen; Rimadyl; Pfizer Ltd, Kent, UK) were administered immediately before the start of surgery. The animal was covered with a plastic sterile drape (Buster Opcover; Buster, Kruuse, Denmark) and with sterile surgical linen drapes on top, such that only the midline incision site was left exposed. Midline abdominal and uterine incisions were then made, the

134 fetal hind limbs were exteriorised minimising amniotic fluid loss and, on one side, fetal femoral
135 arterial (i.d., 0.86 mm; o.d., 1.52 mm; Critchly Electrical Products, NSW, Australia) and venous (i.d.,
136 0.56 mm; o.d., 0.96 mm) catheters were inserted. The catheter tips were advanced to the descending
137 aorta and inferior vena cava, respectively. Another catheter was anchored onto the fetal hind limb for
138 recording of the reference amniotic pressure. A Transonic flow probe was positioned around the
139 contra-lateral femoral artery (MC2RS-JSF-WC120-CS12-GCP, Transonic Systems Inc. Ithaca, New
140 York). The fetal skin incisions were closed with thin linen suture and the uterine incision was closed
141 in layers (3-0 Dexon II Bi-colour; Sherwood, Davis & Geck, Gosport, Hants, UK). The dead space of
142 the catheters was filled with heparinised saline (80 i.u. heparin ml⁻¹ in 0.9% NaCl) and the catheter
143 ends were plugged with sterile brass pins. The fetal head was then palpated and exteriorised through a
144 second uterine incision. The fetal carotid arteries were isolated and on one side a catheter was
145 inserted with the tip remaining in the ascending aorta. A second Transonic flow probe (MC2RS-JSF-
146 WC120-CS12-GCP) was positioned around the contra-lateral carotid artery (Giussani *et al.* 1993) and
147 the fetal skin incision and the second uterine incision were closed as before. All catheters were then
148 exteriorised via a keyhole incision in the maternal flank on the ewe's right side whilst the flow probe
149 leads were exteriorised through a keyhole incision on the ewe's left flank. The maternal peritoneum
150 was then closed in three segments with thick linen suture, and the maternal abdominal skin incision
151 was sewn together (Ethilon 2-0; Ethicon Ltd., Edinburgh, UK). A Teflon catheter (i.d. 1.0 mm, o.d.
152 1.6 mm, Altec, UK) was then inserted into the maternal femoral artery and placed in the descending
153 aorta, and a maternal venous catheter placed in the inferior vena cava (i.d., 0.86 mm; o.d., 1.52 mm;
154 Critchly Electrical Products, NSW, Australia). These catheters were exteriorized through the same
155 key hole on the ewe's right side flank.

156

157 A custom made jacket designed to house the bespoke wireless Cambridge Data Acquisition System
158 (CamDAS, Maastricht Instruments, Maastricht, The Netherlands) was then fitted to the ewe. The
159 CamDAS contained a pressure box and a flow box able to record simultaneously 4 pressure and flow
160 signals, respectively (Figure 1). It was powered by lithium batteries which were also housed within
161 the jacket. The catheters were then connected to pressure transducers (COBE; Argon Division,

162 Maxxim Medical, Athens, TX, USA) within the pressure box and the flow probes were connected to
163 the flow box. Heart rate was triggered from the blood pressure and flow waveforms. Recordings of
164 fetal arterial blood pressure and fetal heart rate, amniotic pressure, fetal carotid blood flow and fetal
165 femoral blood flow could then be continuously transmitted wirelessly via Bluetooth technology onto a
166 laptop computer. At this time the anaesthetic was turned off and the ewe was ventilated until
167 spontaneous respiratory movements were observed. The ewe was extubated when spontaneous
168 breathing returned and the animal was allowed to recover in a floor pen with free access to food and
169 water.

170

171 Ewes wearing jackets with the CamDAS were housed in individual pens in rooms with a
172 12h:12h/light:dark cycle where they had free access to hay and water and were fed concentrates twice
173 daily (100 g sheep nuts no. 6; H & C Beart Ltd, Kings Lynn, UK). Antibiotics were administered daily
174 to the ewe (0.20–0.25 mg kg⁻¹ I.M. depocillin; Mycofarm, Cambridge, UK) for the first three days of
175 recovery and daily to the fetus I.V. and into the amniotic cavity (600 mg in 2 ml 0.9% NaCl,
176 benzylpenicillin; Crystapen, Schering-Plough, Animal Health Division, Welwyn Garden City, UK).
177 Generally, normal feeding patterns were restored within 24–48 h of recovery. Ewes were then
178 randomly allocated to one of two experimental groups: normoxia (n=6) or chronic hypoxia (n=6).

179

180 **Chronic hypoxia protocol**

181 Ewes allocated to chronic hypoxia were housed in one of four bespoke isobaric hypoxic chambers
182 (Telstar Ace, Dewsbury, West Yorkshire, UK; Figure 1). These chambers were supplied with variable
183 amounts of nitrogen and air provided via nitrogen generators and air compressors, respectively, from a
184 custom designed nitrogen generating system (Domnick Hunter Gas Generation, Gateshead, Tyne &
185 Wear, UK). The system operated continuously, automatically switching between adsorption beds of
186 two nitrogen generators (Domnick Hunter N2MAX112 x 2) to ensure a constant provision of pure
187 nitrogen gas. The purity of the nitrogen was monitored to ensure only gas of the required purity
188 reached the application. Compressed air and compressed nitrogen were then piped to the laboratory
189 containing the hypoxic chambers and gases were blended to requirements. The inspirate air mixture

190 underwent a minimum of 12 changes per hour in each chamber and the incoming air mixture was
191 passed via silencers able to reduce noise levels within the hypoxic chamber laboratory (76 dB(A)) and
192 inside each chamber (63 dB(A)) to values lower than those necessary to abide by the Control of Noise
193 at Work Regulations. This not only complied with human health and safety and animal welfare
194 regulations but also provided a tranquil environment for the animal inside each chamber. All
195 chambers were equipped with an electronic automatic humidity cool steam injection system (1100-
196 03239 HS-SINF Masalles, Barcelona, Spain) to ensure appropriate humidity in the inspire
197 ($55\pm 10\%$). Ambient PO_2 , PCO_2 , humidity and temperature within each chamber were monitored via
198 sensors, displayed and values recorded continuously via the Trends Building Management System of
199 the University of Cambridge through a secure Redcare intranet. In this way, the percentage of
200 oxygen in the isolators could be controlled with precision continuously over long periods of time. For
201 experimental procedures, each chamber had a double transfer port to internalise material and a
202 manually operated sliding panel to encourage the ewe into a position where daily sampling of blood
203 could be achieved through glove compartments (Figure 1). Each chamber incorporated a drinking
204 bowl on continuous water supply and a rotating food compartment which could be removed for
205 determining food intake. The chambers were transparent, allowing ewes to visualise each other. A
206 transfer isolation cart could couple two chambers together, allowing ewes to move transiently to an
207 adjacent chamber maintained at the same oxygen environment. This was necessary for cleaning the
208 chambers, which occurred once per week. Therefore, all experimental and maintenance procedures
209 could be carried out without interruption of the hypoxic exposure.

210

211 Pregnancies assigned to the chronic hypoxia group were placed inside the chambers under normoxic
212 conditions ($11 \text{ L}\cdot\text{sec}^{-1}$ air, equating to $39.6 \text{ m}^3\cdot\text{h}^{-1}$) for 2 days. On the 5th post-operative day at 121 ± 1
213 days of gestation, pregnancies assigned to chronic hypoxia were exposed to *ca.* 10% PO_2 by altering
214 the incoming gas mixture to $5 \text{ L}\cdot\text{sec}^{-1}$ air: $6 \text{ L}\cdot\text{sec}^{-1}$ N_2 . The induction of hypoxia was gradual,
215 achieving 10% PO_2 over 24 h. Following 11 days of chronic hypoxia exposure, the pregnancies were
216 returned to breathing normoxic air once again within the chambers. Cardiovascular data were
217 transmitted wirelessly via Bluetooth technology and recorded onto a laptop kept outside the hypoxic

218 chamber laboratory. This permitted continuous *in vivo* recordings of the maternal and fetal
219 cardiovascular data without disturbing the animal's environment.

220

221 Pregnancies allocated to the normoxia group were housed in a barn in floor pens with the same floor
222 area as that of the hypoxic chambers. Both the normoxia and chronic hypoxia groups of ewes were
223 fed daily the same bespoke maintenance diet made up of concentrate pellets and hay (40g nuts/kg and
224 3g hay/kg; Manor Farm Feeds Ltd; Oakham, Leicestershire, UK) to facilitate the monitoring of food
225 intake.

226

227 **Blood sampling regimen and analysis**

228 Samples (0.3 ml) of ascending and descending aortic fetal, as well as descending aortic maternal blood
229 were taken daily for measurement of fetal and maternal blood gas, acid-base and metabolic status.
230 Arterial blood gas and acid base values were measured using an ABL5 blood gas analyser
231 (Radiometer; Copenhagen, Denmark; maternal measurements corrected to 38°C, fetal measurements
232 corrected to 39.5°C). Values for percentage saturation of haemoglobin with oxygen (Sat Hb) and for
233 the concentration of haemoglobin in blood ([Hb]) were determined using a haemoximeter (OSM3;
234 Radiometer). Blood glucose and lactate concentrations were measured using an automated analyser
235 (Yellow Springs 2300 Stat Plus Glucose/Lactate Analyser; YSI Ltd., Farnborough, UK). Values for
236 haematocrit were obtained in duplicate using a microhaematocrit centrifuge (Hawksley, UK). An
237 additional 1 ml of maternal arterial and fetal arterial blood was taken during baseline (24h prior to
238 chronic hypoxia) and at +1h, +6h, +1d, +5d and +10d of chronic hypoxia and at +2d post chronic
239 hypoxia or at equivalent times in normoxic animals for determination of plasma vitamin C and urate
240 concentrations.

241

242 **Determination of plasma urate and vitamin C**

243 Plasma concentrations of urate were measured using an automated Siemens Dimension RxL analyser
244 (Dimension RxL Max integrated Chemistry system, Siemens, UK, Core Biochemical Assay
245 Laboratory, Cambridge, UK). In brief, urate in the plasma (taken from previously unfrozen heparin-

246 treated sample aliquots) is converted to allantoin by the action of uricase (urate oxidase). As urate is
247 able to absorb light at 293 nm but allantoin is not, the change in absorbance at 293 nm is directly
248 proportional to the urate concentration in the sample. Additional dilutions of low calibrator solutions
249 were used to improve the reproducibility of low analyte concentrations. The inter-assay coefficients of
250 variation were 5.0% at 200 $\mu\text{mol/L}$ and 2.7% at 560 $\mu\text{mol/L}$. The lower limit of detection of the assay
251 was 6 $\mu\text{mol/L}$.

252

253 Plasma concentrations of ascorbic acid were measured by a fluorimetric technique using a centrifugal
254 analyser with a fluorescence attachment, according to the method of Vuilleumier and Keck (1989;
255 Core Biochemical Assay Laboratory, Cambridge, UK). In brief, aliquots of maternal and fetal plasma
256 (acidified 1:1 with ice-cold 10 % metaphosphoric acid) were centrifuged and the supernatant stored at
257 -80°C). They were then loaded in duplicate onto a black microtitre plate with standards and quality
258 controls. Addition of ascorbate oxidase converts any vitamin C in the sample to dehydroascorbic acid,
259 which is then condensed with 1,2-phenyldiamine to form a fluorescent quinoxaline derivative. The
260 fluorescence is measured on a Fluoroskan Ascent FL (Fluoroskan Ascent FL Microplate Fluorometer
261 and Luminometer, Thermo Fisher Scientific Inc., UK) and is proportional to the vitamin C
262 concentration in the sample. The inter-assay coefficients of variation were 7.9% at 27.1 $\mu\text{mol/L}$ and
263 5.0% at 89.7 $\mu\text{mol/L}$, the lower limit of detection of the assay was 10 $\mu\text{mol/L}$.

264

265 **Data and statistical analyses**

266 All data are expressed as mean \pm SEM. For the cardiovascular data, minute by minute average values
267 were downloaded continuously throughout the experiment and imported into an Excel spreadsheet.

268 Values during 2 h morning (10:00-12:00) and night-time (22:00-24:00) epochs were then averaged for
269 each day. Fetal arterial blood oxygen content (O_2 content) was calculated using equation (1):

$$270 \quad (1) \quad \text{O}_2 \text{ content (mmol.l}^{-1}\text{)} = \left(\frac{[\text{Hb}] \times \text{SatHb}}{100} \right) \times 0.62$$

271 Where $[\text{Hb}]$ (g.dl^{-1}) is the blood concentration of haemoglobin, SatHb is the percentage oxygen
272 saturation of haemoglobin and where 1 molecule of Hb (M.W. 64,450) binds 4 molecules of oxygen.

273 The contribution of oxygen dissolved in plasma is regarded as negligible (Owens *et al.* 1987).
274 Values for oxygen and for glucose delivery to the fetal ascending and descending aorta were then
275 calculated using equations (2) and (3), respectively:

276 (2) Oxygen delivery ($\mu\text{mol}\cdot\text{min}^{-1}$) = O_2 content ($\mu\text{mol}\cdot\text{ml}^{-1}$) x appropriate flow ($\text{ml}\cdot\text{min}^{-1}$)

277 (3) Glucose delivery ($\mu\text{mol}\cdot\text{min}^{-1}$) = [Glucose] ($\mu\text{mol}\cdot\text{ml}^{-1}$) x appropriate flow ($\text{ml}\cdot\text{min}^{-1}$)

278

279 For statistical analysis, cardiovascular data were analysed comparing the effect of treatment, time and
280 interactions between treatment and time using two-way repeated measures ANOVA with the Tukey's
281 *post hoc* test. Where relevant, area under the curve or slopes were analysed to better summarise the
282 data. Comparison of slopes was performed using the Students *t* test for unpaired data. For all
283 comparisons, statistical significance was accepted when $P < 0.05$.

Results

Maternal food consumption, arterial blood gas, acid base and metabolic status

Basal maternal daily food consumption was not different between groups (N: 1.3 ± 0.9 vs. H: 1.1 ± 0.4 kg.d⁻¹). Exposure to chronic hypoxia did not affect maternal daily food intake (N: 1.5 ± 0.9 vs. H: 1.5 ± 0.9 kg.d⁻¹). Basal values for maternal arterial blood gas, acid-base and metabolic status were not different between groups and were within the normal range for Welsh Mountain ewes at the appropriate time of gestation prior to experimentation (Fletcher *et al.* 2002; 2006 Fig. 2). Ewes exposed to chronic hypoxia had a significant reduction in the partial pressure of arterial oxygen (mean±SEM: 105.7 ± 3.7 to 42.0 ± 1.2 mmHg) and in oxygen saturation (mean±SEM: 103.5 ± 0.5 to $78.6 \pm 5.7\%$) compared to controls (PaO₂: 104.2 ± 1.9 and Sat[Hb]: 92.36 ± 1.5) and their own baseline (P<0.05, Fig. 2). Further, ewes exposed to chronic hypoxia had significantly elevated haematocrit by the end of exposure relative controls (mean±SEM: 33.9 ± 1.0 vs. 28.5 ± 0.9 %). These changes occurred without significant alteration from baseline or between groups in arterial pH, partial pressure of arterial carbon dioxide, acid-base excess, blood glucose or blood lactate concentrations (Fig. 2). Maternal blood lactate concentrations showed a transient 24h increase following the onset of hypoxia, however these alterations did not reach significance. While values for partial pressure of arterial oxygen and oxygen saturation returned towards basal levels, values for haematocrit remained significantly elevated in the chronic hypoxia ewes following re-oxygenation.

Fetal arterial blood gas, acid base and metabolic status

Basal values for descending aortic fetal arterial blood gas, acid-base and metabolic status were similar between groups and were within the normal range for Welsh Mountain singleton sheep fetuses at this stage of gestation (Fletcher *et al.* 2002; 2006, Fig. 3). Fetuses exposed to chronic hypoxia had a significant reduction from baseline in the partial pressure of arterial oxygen (mean±SEM: 20.9 ± 0.5 to 11.5 ± 0.6 mmHg) and oxygen saturation (mean±SEM: 63.0 ± 1.9 to 24.6 ± 2.9 %, P<0.05, Fig. 3). Fetuses exposed to chronic hypoxia also had significantly elevated haematocrit by the end of exposure

311 relative to controls (mean±SEM: 36.1 ± 1.3 vs. 28.0 ± 0.5 , $P < 0.05$). Chronically hypoxic fetuses also
312 showed a transient increase in arterial pH and reductions in acid base excess by the end of the hypoxic
313 period, and sustained falls in the partial pressure of arterial carbon dioxide and increases in blood
314 lactate concentrations during the hypoxic exposure (Fig. 3). These effects occurred without
315 significant alteration from baseline in blood glucose concentrations. While values for all altered
316 variables returned towards baseline, values for haematocrit remained significantly elevated in the
317 chronic hypoxia fetuses following re-oxygenation.

318

319 **Fetal cardiovascular responses**

320 Basal values (mean±SEM) for fetal descending aortic blood pressure (41.1 ± 0.6 vs. 39.2 ± 0.5
321 mmHg), fetal heart rate (186.1 ± 2.0 vs. 177.3 ± 1.8 beats.min⁻¹) carotid blood flow (73.3 ± 3.0 vs.
322 75.7 ± 1.9 ml.min⁻¹) and femoral blood flow (32.3 ± 1.1 vs. 35.5 ± 1.5 ml.min⁻¹) were not different
323 between normoxic and chronic hypoxic groups and were within the normal range for Welsh Mountain
324 singleton sheep fetuses at this stage of gestation (Giussani *et al.* 1993; Jellyman *et al.* 2005; 2009).
325 Fetuses undergoing normoxic pregnancy showed progressive increases in arterial blood pressure (41.1
326 ± 0.6 to 50.1 ± 2.3 mmHg), carotid blood flow (73.3 ± 3.0 to 92.3 ± 7.4 ml.min⁻¹) and femoral blood
327 flow (32.3 ± 1.1 to 35.9 ± 2.5 ml.min⁻¹) and progressive decreases in heart rate (186.1 ± 2.0 to $163.3 \pm$
328 7.0 beats.min⁻¹) with advancing gestational age ($P < 0.05$, Fig. 4). In contrast, in fetuses exposed to
329 chronic hypoxia, the increment in fetal arterial blood pressure with advancing gestation was
330 significantly diminished and the decrement in fetal heart rate occurred much later following the onset
331 of hypoxia but reaching similar levels by the end of the period of exposure (Fig. 4). Further, fetuses
332 exposed to chronic hypoxia showed sustained elevations in both carotid and femoral blood flow
333 during exposure (Table 1 and Fig. 4). While values for carotid and femoral blood flow returned
334 towards basal levels, values for arterial blood pressure and for heart rate remained significantly altered
335 from baseline in the chronic hypoxia fetuses following re-oxygenation.

336 **Fetal ascending and descending aortic oxygen and glucose delivery**

337 Values for oxygen and glucose delivery to the ascending and descending aortic circulations were
338 calculated using the values for oxygen content, blood glucose and blood flow in the relevant
339 circulations shown in Table 1. Fetuses exposed to chronic hypoxia showed significantly reduced
340 values for oxygen delivery to both ascending (227.0 ± 9.8 vs. $256.7 \pm 7.9 \mu\text{mol}\cdot\text{min}^{-1}$) and descending
341 (90.6 ± 4.7 vs. $110.7 \pm 4.7 \mu\text{mol}\cdot\text{min}^{-1}$) aortic circulations relative to normoxic fetuses (Fig. 5).
342 However, when oxygen delivery was expressed as a ratio between vascular beds, there was a
343 significant increase in the oxygen delivery to the ascending relative to the descending aortic
344 circulation during chronic hypoxia ($P < 0.05$, Fig. 5). In contrast, glucose delivery to either ascending
345 or descending aorta was unaltered from baseline in fetuses exposed to chronic hypoxia. However, a
346 significant increase in glucose delivery to the ascending aorta was calculated when expressed as a
347 ratio relative to values for the descending aorta by the end of the experimental protocol (Fig. 5).

348

349 **Maternal and fetal plasma urate and vitamin C concentrations**

350 Values for basal urate concentrations were significantly higher in the fetal (N: $25.5 \pm 1.7 \mu\text{mol}\cdot\text{L}^{-1}$ and
351 H: $21.3 \pm 2.1 \mu\text{mol}\cdot\text{L}^{-1}$) than in the maternal (N: $7.5 \pm 0.8 \mu\text{mol}\cdot\text{L}^{-1}$ and H: $6.6 \pm 0.7 \mu\text{mol}\cdot\text{L}^{-1}$)
352 circulation in both normoxic and hypoxic pregnancy ($P < 0.05$). While fetal plasma urate
353 concentrations increased from baseline in fetuses undergoing chronic hypoxia, plasma urate remained
354 unchanged from baseline in fetuses undergoing normoxic pregnancy and in mothers of normoxic or
355 hypoxic pregnancy (Figure 6). In contrast, values for basal vitamin C concentrations were similar in
356 the fetal (N: $30.4 \pm 4.8 \mu\text{mol}\cdot\text{L}^{-1}$ and H: $31.8 \pm 3.5 \mu\text{mol}\cdot\text{L}^{-1}$) and in the maternal (N: 31.4 ± 4.2
357 $\mu\text{mol}\cdot\text{L}^{-1}$ and H: $33.9 \pm 1.1 \mu\text{mol}\cdot\text{L}^{-1}$) circulation in both normoxic and hypoxic pregnancy. However,
358 while fetal levels of vitamin C remained unchanged from baseline, there was a progressive increase in
359 maternal plasma vitamin C with advancing gestation in both normoxic and hypoxic pregnancy (Figure
360 6).

Discussion

361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380

The data show that exposure of pregnant ewes in late gestation to chronic hypoxia in isobaric chambers led to sustained reductions in fetal PaO₂ to mean levels of *ca.* 11 mmHg and therefore similar to those measured in human infants of hypoxic IUGR pregnancy (Hecher *et al.* 1995) whilst not affecting maternal food intake. Chronic fetal hypoxia of this magnitude was accompanied by sustained reductions in fetal PaCO₂, progressive increases in fetal haematocrit and variable increases in fetal blood lactate levels. Chronically hypoxic fetuses showed an impaired ontogenic increase in arterial blood pressure and a delayed ontogenic fall in fetal heart rate with advancing gestation. Parallel recording of carotid and femoral blood flow revealed sustained increases during the period of chronic hypoxia in chronically hypoxic fetuses, which were greater than those measured in normoxic fetuses with advancing gestation. The ratio of oxygen and glucose delivery to the fetal carotid circulation relative to the femoral circulation increased significantly and progressively in the chronically hypoxic fetus. Basal plasma urate concentrations were higher in the fetus than in the mother and plasma urate increased significantly in the chronically hypoxic fetus. Conversely, basal plasma ascorbic acid concentrations were similar in the mother and fetus and plasma ascorbic acid increased to similar extents only in the maternal circulation in normoxic and hypoxic pregnancy. These data support the hypotheses tested that the fetal brain sparing response persists during significant chronic fetal hypoxia and that an increase in ROS in the fetal circulation is an involved mechanism.

381
382
383
384
385
386
387
388

Several compensatory responses to hypoxia are regulated at least in part by the hypoxia-inducible factor (HIF) family of transcription factors (Semenza, 2004). These coordinate intracellular responses to hypoxia by regulating the expression of hundreds of genes, including erythropoietin or *EPO*. The increased expression of the glycoprotein erythropoietin leads to increased red blood cell production, which can be measured as an elevation in packed red cell volume or the haematocrit. The present data confirm that this level of chronic hypoxia led to significant activation of the HIF-regulated gene product erythropoietin, as the fetal and to a lesser extent maternal haematocrit increased progressively

389 during and immediately following the period of chronic hypoxia. Additional blood data in the present
390 manuscript show that chronic hypoxia was accompanied by significant and sustained hypocapnia in
391 the fetal but not in the maternal circulation. Fetal hypocapnia could be due to a shift in the fetal
392 oxidative metabolism, decreasing fetal oxygen consumption and thereby fetal CO₂ production and/or
393 faster clearance of CO₂ from the fetal to the maternal circulation. The sustained elevation in fetal
394 rather than maternal blood lactate concentration during chronic hypoxia in the present manuscript
395 indicates an increase in fetal anaerobic metabolism, as has been previously suggested during hypoxic
396 pregnancy (Lueder *et al.* 1995; Thompson, 2003). Bacon *et al.* (1984) also reported changes in
397 placental barrier thickness and/or blood flow in chronically hypoxic guinea pig pregnancy.

398

399 Several studies have reported ontogenic increases in fetal arterial blood pressure and fetal peripheral
400 blood flow and decreases in fetal heart rate with advancing gestation in several species (Reeves *et al.*
401 1972; Boddy *et al.* 1974; Dawes *et al.* 1980; MacDonald *et al.* 1983; Kitanaka *et al.* 1989; Forhead *et*
402 *al.* 2000; Giussani *et al.* 2005). The present data are the first to report ontogenic increases in carotid
403 blood flow with advancing gestation in control fetal sheep. One previous study reported lower mean
404 values for fetal arterial blood pressure in chronically hypoxic fetuses of placentally-restricted (PR)
405 pregnancies (Edwards *et al.* 1999). However, others using the same PR model or in hypoxic fetuses
406 from ovine pregnancies exposed to mild chronic hypoxia have reported similar fetal blood pressure
407 between control and experimental animals (Kitanaka *et al.* 1989; Pulgar *et al.* 2006; 2007; 2009;
408 Danielson *et al.* 2005; Poudel *et al.* 2015). By comparison, elevated basal values and alterations in
409 the developmental decline of fetal heart rate with advancing gestation have been more consistently
410 reported for the chronically hypoxic sheep fetus (Kitanaka *et al.* 1989; Pulgar *et al.* 2006). These
411 findings are in keeping with a sympathetic dominant influence on cardiovascular control in the
412 chronically hypoxic fetus (Kitanaka *et al.* 1989; Edwards *et al.* 1999). That blood flow to the fetal
413 cerebral vascular bed increases in a sustained manner in response to chronic hypoxia has been
414 established for many years (Richardson *et al.* 1993; Richardson & Bocking, 1998). In contrast, it has
415 been generally assumed but widely accepted that blood flow to the peripheral circulations is decreased
416 in the chronically hypoxic fetus and that this sustained redistribution of blood flow away from the

417 periphery contributes to the repeatedly reported asymmetric growth restriction in the chronically
418 hypoxic fetus (see Barker, 1996; Giussani, 2015). Two studies support lower basal values for femoral
419 (Poudel *et al.* 2015) and carcass (Kamitomo *et al.* 1993) blood flow in the chronically hypoxic fetus,
420 with single time point measurements with microspheres or acute recordings of femoral blood flow for
421 2h. In this manuscript, we report that continuous longitudinal measurement of fetal femoral blood
422 flow reveals a sustained increase during chronic hypoxia, akin to the peripheral dilator response to
423 hypoxia in the adult individual or to the enhanced basal femoral blood flow in adult offspring of
424 chronically hypoxic pregnancy (Coney & Marshall, 2010). However, when calculating the actual
425 delivery of oxygen and glucose to regional circulations, the ratio of substrate delivery to the carotid
426 relative to the femoral circulation in the fetus shows a progressive increase as the chronic hypoxia
427 develops. The latter provides first-hand evidence for persistent brain sparing and continued
428 redistribution of oxygen delivery away from peripheral circulations and towards the brain in the
429 chronically hypoxic fetus.

430

431 The use of *in vivo* models to address questions regarding ROS generation comes with complications,
432 as free radicals, by their very nature, are difficult to measure in these preparations. This problem is
433 further compounded in the present study due to relative inaccessibility of the fetus within the
434 intrauterine environment within a hypoxic chamber. Nevertheless, of all techniques available,
435 dynamic changes in urate and ascorbate concentrations in plasma constitute two of the few accepted
436 biomarkers of ROS generation within the circulation *in vivo* (Halliwell & Gutteridge, 2004). Plasma
437 urate concentration is an established marker of the activation of the xanthine oxidase (XO) pathway
438 and, hence, of $\bullet\text{O}_2^-$ generation (Berry & Hare, 2004). In sheep, ascorbate forms part of the
439 endogenous antioxidant defence since ovine species possess the enzyme gulonolactone oxidase which
440 promotes the *de novo* synthesis of ascorbate via the hexuronic acid pathway of the liver and/or kidney
441 (Banhegyi *et al.* 1997). It is established that plasma ascorbate concentrations also increase throughout
442 gestation in several species, consistent with a functional role for this antioxidant in prenatal life (Kolb
443 *et al.* 1991). We have previously reported the discovery that enhanced ROS generation contributes to
444 the fetal peripheral vasoconstrictor response to an episode of acute hypoxia, part of the fetal brain

445 sparing effect (Thakor *et al.* 2010; 2015; Kane *et al.* 2012; 2014). ROS do so by quenching NO and
446 promoting a vascular oxidant tone that complements carotid chemoreflex and endocrine constrictor
447 mechanisms, aiding the redistribution of blood flow away from peripheral circulations (Giussani,
448 2015). Data in the present study suggest that there may be tonic activation of the XO pathway during
449 basal conditions in the fetus relative to the mother, and that the XO pathway in the fetus is more
450 sensitive to chronic hypoxia than the mother. Since basal arterial PaO₂ is about a quarter lower in the
451 fetal than in the maternal arterial circulation, it is tempting to speculate that the XO pathway is more
452 active during basal conditions and more responsive to chronic hypoxia in fetal than in adult life,
453 purely by virtue of this difference in oxygenation (Everest *in utero*; Barcroft *et al.* 1993). The
454 significant increase in plasma urate concentrations in the circulation of the chronically hypoxic fetus
455 is consistent with sustained activation of the XO pathway and continued excess ROS generation.
456 Sustained XO-derived ROS generation may thus contribute to the vascular oxidant tone of the fetal
457 peripheral circulations, aiding in the shift in the delivery of oxygenated blood away from the fetal
458 femoral and towards the fetal cerebral circulation in chronically hypoxic pregnancy of this magnitude.
459 However, it is also possible that differences in circulating urate concentrations between mother and
460 fetus reflect, in part, different rates of protein degradation and/or differences in renal clearance in the
461 ewe and offspring.

462

463 Historically, there have been seminal investigations which have induced chronic fetal hypoxia by
464 impairing uteroplacental blood flow by carunclectomy (Robinson *et al.* 1979; Poudel *et al.* 2015),
465 placental embolization (Boyle *et al.* 1984; Gagnon *et al.* 1997; Block *et al.* 1984), restriction of
466 uterine blood flow (Richardson & Bocking, 1998; Stein *et al.* 1999; Lang *et al.* 2000), single
467 umbilical artery ligation (Supramaniam *et al.* 2006; Oyama *et al.* 1992) and umbilical cord
468 compression (Itskovitz *et al.* 1987; Giussani *et al.* 1997). However, all of these experimental
469 manipulations reduce nutrient as well as oxygen delivery to the fetal circulation, preventing
470 elucidation of the effects of chronic hypoxia on fetal cardiovascular function in isolation. Other
471 equally important contributions have included description of fetal or neonatal cardiovascular function
472 at the conclusion of the chronic hypoxic exposure (Rouwet *et al.* 2002; Sharma *et al.* 2006; Tintu *et*

473 *al.* 2007; Herrera *et al.* 2008, 2012; Camm *et al.* 2010; Lindgren & Altimiras, 2013; Iversen *et al.*
474 2014). A cluster of studies has investigated the effects of chronic hypoxia on fetal cardiovascular
475 function *in vivo*, but only reported effects on fetal arterial blood pressure, heart rate and ventricular
476 output (Alonso *et al.* 1989; Kitanaka *et al.* 1989; Kamitomo *et al.* 1994; Pulgar *et al.* 2006; 2007;
477 2009; Tissot van Patot *et al.* 2012). Another significant series of investigations has exploited the
478 natural hypobaric hypoxia of high altitude to study the effects on fetal cardiovascular function of
479 long-term hypoxic gestation (Kamitomo *et al.* 1992, 1993, 2002; Browne *et al.* 1997a, 1997b; Onishi
480 *et al.* 2003). While these studies have provided highly important contributions to the field of
481 knowledge, exposure of pregnant ewes to altitudes between 3000 and 4500 m above sea level yields
482 late gestation fetal arterial PO₂ levels between 15-19 mmHg (Kamitomo *et al.* 1992, 1993, 2002;
483 Browne *et al.* 1997a, 1997b; Onishi *et al.* 2003; Tissot van Patot *et al.* 2012). These values are much
484 milder than those measured in the umbilical cord of the human hypoxic fetus in IUGR pregnancy,
485 which are closer to 10-12 mmHg (Hecher *et al.* 1995). Investigation of this level of significant
486 chronic fetal hypoxia using high altitude would involve exposure at 6500-7000 m above sea level
487 (Gallagher & Hackett, 2004). Therefore, in summary, the work presented has introduced to the field
488 of study a new technique for physiological research able to maintain chronically instrumented
489 maternal and fetal sheep for prolonged periods of gestation under significant and controlled isolated
490 chronic fetal hypoxia beyond levels that can be achieved by habitable high altitude. This technology
491 also permits real time wireless recording in free moving animals of *in vivo* continuous maternal and
492 fetal cardiovascular function, including alterations in regional blood flow signals as the hypoxic
493 pregnancy is developing. Bioethically, the technology not only improves the physiological quality of
494 the maternal and fetal *in vivo* data but it also improves animal welfare. This is the first time that this
495 has been possible.

496

Acknowledgements

497

498 This work was supported by the British Heart Foundation. Dino Giussani is the Professor of
499 Cardiovascular Developmental Physiology & Medicine at the Department of Physiology Development
500 & Neuroscience at the University of Cambridge, Professorial Fellow and Director of Studies in
501 Medicine at Gonville & Caius College, a Lister Institute Fellow and a Royal Society Wolfson
502 Research Merit Award Holder. We would like to thank Professor Abigail L. Fowden for continuous
503 encouragement and insightful scientific discussion.

504

505

Author contributions

506

507 The experiments in this study were performed in the Department of Physiology, Development and
508 Neuroscience, University of Cambridge. DAG, EAH and ADK worked with Telstar ACE to design
509 the hypoxic chambers and with Maatricht Instruments to design and create the data acquisition
510 system. BJA, KLB, YN, ADK, EAH, AST, KJB, CMC, NI, KLS, CB and DAG conceived and
511 designed the experiments. BJA, KLB, YN, ADK, EAH, AST, KJB, CMC, NI, KLS, CB and DAG
512 collected, analysed and interpreted the experimental data. BJA, KLB, YN, ADK, EAH, AST, KJB,
513 CMC, NI, KLS, CB and DAG drafted the article and revised it critically for important intellectual
514 content.

515

516

Disclosure

517 License agreement 100395 CamDAS: Technology for simultaneous wireless recording of arterial blood
518 pressure and blood flow in large animals. Giussani, D.A., Maatricht Instruments and Cambridge
519 Enterprise.

Legends

520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544

Table 1. Variables used to calculate oxygen and glucose delivery in the chronically hypoxic fetus.

Values are mean±S.E.M variables required to calculate oxygen and glucose delivery throughout the experimental protocol. Data are shown for fetal ascending and descending arterial oxygen content, blood glucose and flows in normoxic (N) and hypoxic (H) fetuses (n= 6 both groups). Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test).

Figure 1. Isobaric hypoxic chambers and the CamDAS system. Each chamber was equipped with an electronic servo-controlled humidity cool steam injection system to return the appropriate humidity to the inspire (i). Ambient PO₂, PCO₂, humidity and temperature within each chamber were monitored via sensors (ii). For experimental procedures, each chamber had a double transfer port (iii) to internalise material and a manually-operated sliding panel (iv) to bring the ewe into a position where daily sampling of blood could be achieved through glove compartments (v). Each chamber incorporated a drinking bowl on continuous water supply and a rotating food compartment (vi) for determining food intake. A sealed transfer isolation cart could be attached to a side exit (vii) to couple chambers together for cleaning. The CamDAS system was contained in a custom-made sheep jacket able to hold the pressure acquisition system box (ix) in one side pouch and a box containing the Transonic flow probe connectors (x) in the other. Cables (xi) connected the two boxes together and also linked to two battery packs able to power the system for 24 hours. Measurements made using the data acquisition were transmitted wirelessly via Bluetooth (xiii) to a laptop kept outside the chamber room (xii) on which it was possible to view continuous recordings of the maternal and fetal cardiovascular data.

545 **Figure 2. Maternal blood gas, acid base and metabolic status.** Values are mean±S.E.M. for
546 pregnant sheep undergoing normoxic (○, n=6) or chronic hypoxic (●, n=6) pregnancy. Maternal
547 blood gas values were corrected to 38°C. pH, arterial pH; PaCO₂, arterial CO₂ partial pressure; PaO₂,
548 arterial O₂ partial pressure; Sat[Hb], percentage saturation of haemoglobin; ABE, acid/base excess;
549 Htc, haematocrit; Glucose, blood glucose concentration; Lactate, blood lactate concentration; (N),
550 normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main
551 effect of time compared with baseline; †, differences indicating a significant main effect of treatment
552 compared with normoxic pregnancy (two way RM ANOVA + Tukey test). For Htc, the comparison
553 of slopes was achieved with the Student's *t* test for unpaired data.

554

555 **Figure 3. Fetal blood gas, acid base and metabolic status.** Values are mean±S.E.M. for fetal sheep
556 undergoing normoxic (○, n=6) or chronic hypoxic (●, n=6) pregnancy. Fetal blood gas values were
557 corrected to 39.5°C. pH, arterial pH; PaCO₂, arterial CO₂ partial pressure; PaO₂, arterial O₂ partial
558 pressure; Sat[Hb], percentage saturation of haemoglobin; ABE, acid/base excess; Htc, haematocrit;
559 Glucose, blood glucose concentration; Lactate, blood lactate concentration; d, days; hr, hour; (N),
560 normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main
561 effect of time compared with baseline; †, differences indicating a significant main effect of treatment
562 compared with normoxic pregnancy (two way RM ANOVA + Tukey test).

563

564 **Figure 4. Fetal cardiovascular responses to chronic hypoxia.** Values are mean±S.E.M. for the
565 change from baseline in cardiovascular variables in fetal sheep undergoing normoxic (○, n=6, left) or
566 chronic hypoxic (●, n=6, right) pregnancy. CBF, carotid blood flow; FBF, femoral blood flow; d,
567 days; hr, hour; BPM, beats per minute; (N), normoxic recovery. Significant differences (P<0.05): *,
568 differences indicating a significant main effect of time compared with baseline; †, differences
569 indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM
570 ANOVA + Tukey test). For Descending aortic pressure, the two-way ANOVA represents a
571 comparison of slopes. For FBF and CBF, the two-way ANOVA represents a comparison of areas
572 under the curve.

573 **Figure 5. Fetal carotid and femoral arterial oxygen and glucose delivery in the chronically**
574 **hypoxic fetus.** Values are mean±S.E.M. for the change from baseline in oxygen and glucose delivery
575 in the ascending and the descending aorta and the ratio of these values in fetal sheep undergoing
576 normoxic (○, n=6) or chronic hypoxic (●, n=6) pregnancy. d, days; hr, hour; (N), normoxic recovery.
577 Significant differences (P<0.05): *, differences indicating a significant main effect of time compared
578 with baseline; †, differences indicating a significant main effect of treatment compared with normoxic
579 pregnancy (two way RM ANOVA + Tukey test). For the ratio of ascending:descending oxygen
580 delivery, the two way ANOVA represents an analysis of the area under the curve.

581

582 **Figure 6. Fetal and maternal vitamin C and urate levels in the chronically hypoxic fetus.** Values
583 are mean±S.E.M. for the change from baseline in vitamin C and urate in pregnant ewes and fetal
584 sheep undergoing normoxic (○, fetus; □, ewe; n=6) or chronic hypoxic (●, fetus; ■, ewe; n=6)
585 pregnancy. d, days; hr, hour; (N), normoxic recovery. Significant differences (P<0.05): *, differences
586 indicating a significant main effect of time compared with baseline; †, differences indicating a
587 significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA +
588 Tukey test). For the fetal urate levels the two way ANOVA represents an analysis of the area under
589 the curve.

References

590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615

Alonso JG, Okai T, Longo LD & Gilbert RD. (1989). Cardiac function during long-term hypoxemia in fetal sheep. *The American Journal of Physiology* 257, H581-589.

Bacon BJ, Gilbert RD, Kaufmann P, Smith AD, Trevino FT, Longo LD (1984). Placental anatomy and diffusing capacity in guinea pigs following long-term maternal hypoxia. *Placenta* 5(6), 475-87.

Banhegyi G, Braun L, Csala M, Puskas F & Mandl J (1997). Ascorbate metabolism and its regulation in animals. *Free Radic Biol Med* 23, 793-803.

Barcoft J, Herkel W, Hill S (1933). The rate of blood flow and gaseous metabolism of the uterus during pregnancy. *J Physiol* 77, 194-206.

Barker DJP (1998). *Mothers, Babies, and Disease in Later Life* (Churchill Livingstone, Edinburgh, UK).

Bartelds B, van Bel F, Teitel DF & Rudolph AM. (1993). Carotid, not aortic, chemoreceptors mediate the fetal cardiovascular response to acute hypoxemia in lambs. *Pediatric Research* 34, 51-55.

Berry C & Hare M (2004). Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. *J Physiol* 555, 589–606.

Block BS, Llanos AJ, Creasy RK (1984). Responses of the growth-retarded fetus to acute hypoxemia. *Am J Obstet Gynecol* 148(7), 878-85.

616 Boddy K, Dawes GS, Fisher R, Pinter S & Robinson JS (1974), Foetal respiratory movements
617 electrocortical and cardiovascular responses to hypoxaemia and hypercapnia in sheep. *J Physiol* 243,
618 599-618.

619

620 Boyle JW, Lotgering FK & Longo LD. (1984). Acute embolization of the uteroplacental circulation:
621 uterine blood flow and placental CO diffusing capacity. *Journal of developmental physiology* 6, 377-
622 386.

623

624 Browne VA, Stiffel VM, Pearce WJ, Longo LD & Gilbert RD. (1997a). Activator calcium and
625 myocardial contractility in fetal sheep exposed to long-term high-altitude hypoxia. *The American*
626 *Journal of Physiology* 272, H1196-1204.

627

628 Browne VA, Stiffel VM, Pearce WJ, Longo LD & Gilbert RD. (1997b). Cardiac beta-adrenergic
629 receptor function in fetal sheep exposed to long-term high-altitude hypoxemia. *The American Journal*
630 *of Physiology* 273, R2022-2031.

631

632 Burton GJ. (2009). Oxygen, the Janus gas; its effects on human placental development and function.
633 *Journal of Anatomy* 215, 27-35.

634

635 Camm EJ, Hansell JA, Kane AD, Herrera EA, Lewis C, Wong S, Morrell NW, Giussani DA (2010).
636 Partial contributions of developmental hypoxia and undernutrition to prenatal alterations in somatic
637 growth and cardiovascular structure and function. *Am J Obstet Gynecol.* 203(5), 495.e24-34.

638

639 Cohn HE, Sacks EJ, Heymann MA & Rudolph AM (1974). Cardiovascular responses to hypoxemia
640 and acidemia in fetal lambs. *Am J Obstet Gynecol* 120, 817-824.

641

642 Compernelle V, Brusselmans K, Franco D, Moorman A, Dewerchin M, Collen D & Carmeliet P.
643 (2003). Cardia bifida, defective heart development and abnormal neural crest migration in embryos
644 lacking hypoxia-inducible factor-1alpha. *Cardiovascular Research* 60, 569-579.

645

646 Coney AM1, Marshall JM (2010). Effects of maternal hypoxia on muscle vasodilatation evoked by
647 acute systemic hypoxia in adult rat offspring: changed roles of adenosine and A1 receptors. *J Physiol.*
648 588(Pt 24), 5115-25.

649

650 Danielson L, McMillen IC, Dyer JL, Morrison JL (2005). Restriction of placental growth results in
651 greater hypotensive response to alpha-adrenergic blockade in fetal sheep during late gestation. *J*
652 *Physiol.* 563(Pt 2), 611-20.

653

654 Davis L, Thornburg KL, Giraud GD (2005). The effects of anaemia as a programming agent in the
655 fetal heart. *J Physiol* 565(Pt 1), 35-41.

656

657 Dawes GS, Johnston BM & Walker DW (1980). Relationship of arterial pressure and heart rate in
658 fetal, new-born and adult sheep. *J Physiol* 309, 405-417.

659

660 Edwards LJ, Simonetta G, Owens JA, Robinson JS & McMillen IC. (1999). Restriction of placental
661 and fetal growth in sheep alters fetal blood pressure responses to angiotensin II and captopril. *The*
662 *Journal of physiology* 515 (Pt 3), 897-904.

663

664 Escobar J, Teramo K, Stefanovic V, Andersson S, Asensi MA, Arduini A, Cubells E, Sastre J, Vento
665 M (2013). Amniotic fluid oxidative and nitrosative stress biomarkers correlate with fetal chronic
666 hypoxia in diabetic pregnancies. *Neonatology*103(3), 193-8.

667

668 Fletcher AJ, Goodfellow MR, Forhead AJ, Gardner DS, McGarrigle HH, Fowden AL, Giussani DA
669 (2000). Low doses of dexamethasone suppress pituitary-adrenal function but augment the glyce-
670 mic response to acute hypoxemia in fetal sheep during late gestation. *Pediatr Res.* 47(5), 684-91.
671

672 Fletcher AJ, McGarrigle HH, Edwards CM, Fowden AL, Giussani DA (2002). Effects of low dose
673 dexamethasone treatment on basal cardiovascular and endocrine function in fetal sheep during late
674 gestation. *J Physiol.* 545(Pt 2), 649-60.
675

676 Fletcher AJ, Gardner DS, Edwards CM, Fowden AL, Giussani DA (2006). Development of the ovine
677 fetal cardiovascular defense to hypoxemia towards full term. *Am J Physiol Heart Circ Physiol* 291(6),
678 H3023-34.
679

680 Forhead AJ, Broughton Pipkin F, Taylor PM, Baker K, Balouzet V, Giussani DA & Fowden AL
681 (2000). Developmental changes in blood pressure and the renin-angiotensin system in Pony fetuses
682 during the second half of gestation. *J Reprod Fert Suppl* 56, 693-703.
683

684 Gallagher SA & Hackett PH. (2004). High-altitude illness. *Emergency medicine clinics of North*
685 *America* 22, 329-355, viii.
686

687 Gagnon R, Murotsuki J, Challis JR, Fraher L & Richardson BS. (1997). Fetal sheep endocrine
688 responses to sustained hypoxemic stress after chronic fetal placental embolization. *The American*
689 *journal of physiology* 272, E817-823.
690

691 Giussani DA, Spencer JA, Moore PJ, Bennet L & Hanson MA (1993). Afferent and efferent
692 components of the cardiovascular reflex responses to acute hypoxia in term fetal sheep. *J Physiol* 461,
693 431-449.
694

695 Giussani DA, Spencer JA & Hanson MA. (1994). Fetal cardiovascular reflex responses to hypoxia.
696 Fetal and Maternal Medicine Review 6, 17-37.
697
698 Giussani DA, Unno N, Jenkins SL, Wentworth RA, Derks JB, Collins JH, Nathanielsz PW (1997).
699 Dynamics of cardiovascular responses to repeated partial umbilical cord compression in late-gestation
700 sheep fetus. Am J Physiol. 273(5 Pt 2), H2351-60.
701
702 Giussani DA, Phillips PS, Anstee S & Barker DJ. (2001). Effects of altitude versus economic status on
703 birth weight and body shape at birth. Pediatric Research 49, 490-494.
704
705 Giussani DA, Forhead AJ, Fowden AL (2005). Development of cardiovascular function in the horse
706 fetus. J Physiol. 565(Pt 3), 1019-30.
707
708 Giussani DA, Davidge ST (2013). Developmental programming of cardiovascular disease by prenatal
709 hypoxia. J Dev Orig Health Dis 4(5), 328-37.
710
711 Gunn AJ, Bennet L (2009). Fetal hypoxia insults and patterns of brain injury: insights from animal
712 models. Clin Perinatol. 36(3), 579-93.
713
714 Halliwell B & Gutteridge JMC. (2004). Free Radicals in Biology and Medicine. Oxford University
715 Press, Oxford.
716
717 Hayes EK, Lechowicz A, Petrik JJ, Storozhuk Y, Paez-Parent S, Dai Q, Samjoo IA, Mansell M,
718 Gruslin A, Holloway AC, Raha S (2012). Adverse fetal and neonatal outcomes associated with a life-
719 long high fat diet: role of altered development of the placental vasculature. PLoS One. 7(3), e33370.
720

721 Hecher K, Snijders R, Campbell S & Nicolaides K. (1995). Fetal venous, intracardiac, and arterial
722 blood flow measurements in intrauterine growth retardation: Relationship with fetal blood gases.
723 American Journal of Obstetrics and Gynecology 173, 10-15.
724

725 Herrera EA, Reyes RV, Giussani DA, Riquelme RA, Sanhueza EM, Ebensperger G, Casanello P,
726 Méndez N, Ebensperger R, Sepúlveda-Kattan E, Pulgar VM, Cabello G, Blanco CE, Hanson MA,
727 Parer JT, Llanos AJ (2008). Carbon monoxide: a novel pulmonary artery vasodilator in neonatal
728 llamas of the Andean altiplano. Cardiovasc Res. 77(1), 197-201.
729

730 Herrera EA, Camm EJ, Cross CM, Mullender JL, Wooding FB, Giussani DA (2012). Morphological
731 and functional alterations in the aorta of the chronically hypoxic fetal rat. J Vasc Res. 49(1):50-8.
732

733 Huch A, Huch R, Schneider H & Rooth G (1977). Continuous transcutaneous monitoring of fetal
734 oxygen tension during labour. Br J Obstet Gynaecol 84 Suppl 1, 1-39.
735

736 Itskovitz J, LaGamma EF, Rudolph AM (1987). Effects of cord compression on fetal blood flow
737 distribution and O₂ delivery. Am J Physiol 252(1 Pt 2), H100-9.
738

739 Iversen NK1, Wang T, Baatrup E, Crossley DA 2nd (2014). (The role of nitric oxide in the
740 cardiovascular response to chronic and acute hypoxia in White Leghorn chicken (*Gallus domesticus*).
741 Acta Physiol 211(2), 346-57.
742

743 Jellyman JK, Gardner DS, Edwards CM, Fowden AL, Giussani DA (2005). Fetal cardiovascular,
744 metabolic and endocrine responses to acute hypoxaemia during and following maternal treatment with
745 dexamethasone in sheep. J Physiol 567(Pt 2), 673-88.
746

747 Jellyman JK, Gardner DS, McGarrigle HH, Fowden AL, Giussani DA (2009). Antenatal
748 glucocorticoid therapy increases glucose delivery to cerebral circulations during acute hypoxemia in
749 fetal sheep during late gestation. *Am J Obstet Gynecol* 201(1), 82.e1-8.
750

751 Jones CT, Robinson RO (1975). Plasma catecholamines in foetal and adult sheep. *J Physiol* 248(1),
752 15-33.
753

754 Kamitomo M, Longo LD & Gilbert RD. (1992). Right and left ventricular function in fetal sheep
755 exposed to long-term high-altitude hypoxemia. *The American Journal of Physiology* 262, H399-405.
756

757 Kamitomo M, Alonso JG, Okai T, Longo LD & Gilbert RD. (1993). Effects of long-term, high-
758 altitude hypoxemia on ovine fetal cardiac output and blood flow distribution. *Am J Obstet Gynecol*
759 169, 701-707.
760

761 Kamitomo M, Longo LD & Gilbert RD. (1994). Cardiac function in fetal sheep during two weeks of
762 hypoxemia. *The American Journal of Physiology* 266, R1778-1785.
763

764 Kamitomo M, Onishi J, Gutierrez I, Stiffel VM & Gilbert RD. (2002). Effects of long-term hypoxia
765 and development on cardiac contractile proteins in fetal and adult sheep. *Journal of the Society for*
766 *Gynecologic Investigation* 9, 335-341.
767

768 Kane AD, Herrera EA, Hansell JA, Giussani DA (2012). Statin treatment depresses the fetal defence
769 to acute hypoxia via increasing nitric oxide bioavailability. *J Physiol* 590(Pt 2), 323-34.
770

771 Kane AD, Hansell JA, Herrera EA, Allison BJ, Niu Y, Brain KL, Kaandorp JJ, Derks JB, Giussani
772 DA (2014). Xanthine oxidase and the fetal cardiovascular defence to hypoxia in late gestation ovine
773 pregnancy. *J Physiol* 592(Pt 3):475-89.

774

775 Kaplan-Sturk R, Åkerud H, Volgsten H, Hellström-Westas L, Wiberg-Itzel E (2013). Outcome of
776 deliveries in healthy but obese women: obesity and delivery outcome. *BMC Res Notes* 6, 50.

777

778 Katz O, Sheiner E (2008). Asthma and pregnancy: a review of two decades. *Expert Rev Respir Med*
779 2(1), 97-107.

780

781 Kingdom JC, Kaufmann P (1997). Oxygen and placental villous development: origins of fetal
782 hypoxia. *Placenta* 18(8), 613-21.

783

784 Kitanaka T, Alonso JG, Gilbert RD, Siu BL, Clemons GK & Longo LD. (1989). Fetal responses to
785 long-term hypoxemia in sheep. *The American Journal of Physiology* 256, R1348-1354.

786

787 Kolb E, Wahren M, Leo M, Siebert P, Erices J, Gollnitz L & Volker L. (1991). [Ascorbic acid
788 concentration in plasma, in amniotic and allantoic fluids, in the placenta and in 13 tissues of sheep
789 fetuses and newborn lambs]. *DTW Deutsche tierärztliche Wochenschrift* 98, 424-427.

790

791 Lang U, Baker RS, Khoury J & Clark KE. (2000b). Effects of chronic reduction in uterine blood flow
792 on fetal and placental growth in the sheep. *American Journal of Physiology (Regulatory, Integrative
793 and Comparative Physiology)* 279, R53-59.

794

795 Lindgren I & Altimiras J. (2013). Prenatal hypoxia programs changes in beta-adrenergic signaling and
796 postnatal cardiac contractile dysfunction. *American Journal of Physiology (Regulatory, Integrative
797 and Comparative Physiology)* 305, R1093-1101.

798

799 Longo LD (1976). Carbon monoxide: effects on oxygenation of the fetus in utero. *Science* 194(4264),
800 523-5.

801

802 Low JA, Galbraith RS, Muir DW, Killen HL, Pater EA & Karchmar EJ (1985). The relationship
803 between perinatal hypoxia and newborn encephalopathy. *Am J Obstet Gynecol* 152, 256-260.

804

805 Lueder FL, Kim SB, Buroker CA, Bangalore SA, Ogata ES (1995). Chronic maternal hypoxia retards
806 fetal growth and increases glucose utilization of select fetal tissues in the rat. *Metabolism* 44(4), 532-
807 7.

808

809 Maberry MC, Ramin SM, Gilstrap LC 3rd, Leveno KJ, Dax JS (1990). Intrapartum asphyxia in
810 pregnancies complicated by intra-amniotic infection. *Obstet Gynecol* 76(3 Pt 1), 351-4.

811

812 Macdonald AA, Colenbrander B & Wensing CJG (1983). The effects of gestational age and chronic
813 fetal decapitation on arterial blood pressure in the fetus. *Eur J Obstet & Gynaecol Reprod Biol* 16, 63-
814 70.

815

816 Makowski EL, Battaglia FC, Meschia G, Behrman RE, Schrufer J, Seeds AE, Bruns PD (1968).
817 Effect of maternal exposure to high altitude upon fetal oxygenation. *Am J Obstet Gynecol.* 100(6),
818 852-6.

819

820 Marshall JM (1999). The Joan Mott Prize Lecture. The integrated response to hypoxia: from
821 circulation to cells. *Exp Physiol* 84(3), 449-70..

822

823 Onishi J, Kamitomo M, Stiffel VM & Gilbert RD. (2003). Effects of long-term high-altitude hypoxia
824 on myocardial protein kinase A activity and troponin I isoforms in fetal and nonpregnant sheep.
825 *Journal of the Society for Gynecologic Investigation* 10, 189-193.

826

827 Oyama K, Padbury J, Chappell B, Martinez A, Stein H & Humme J. (1992). Single umbilical artery
828 ligation-induced fetal growth retardation: effect on postnatal adaptation. *The American Journal of*
829 *Physiology* 263, E575-583.

830

831 Owens JA, Falconer J and Robinson JS (1987). Effect of restriction of placental growth on oxygen
832 delivery to and consumption by the pregnant uterus and fetus. *J Dev Physiol* 9, 137-150.

833

834 Pardi G, Cetin I, Marconi AM, Lanfranchi A, Bozzetti P, Ferrazzi E, Buscaglia M, Battaglia FC
835 (1993). Diagnostic value of blood sampling in fetuses with growth retardation. *N Engl J Med* 328(10),
836 692-6.

837

838 Poudel R, McMillen IC, Dunn SL, Zhang S, Morrison JL (2015). Impact of chronic hypoxemia on
839 blood flow to the brain, heart, and adrenal gland in the late-gestation IUGR sheep fetus. *Am J Physiol*
840 *Regul Integr Comp Physio* 308(3), R151-62.

841

842 Pulgar VM, Zhang J, Massmann GA, Figueroa JP (2006). Prolonged mild hypoxia alters fetal sheep
843 electrocorticogram activity. *J Soc Gynecol Investig.* 13(6), 404-11.

844

845 Pulgar VM, Zhang J, Massmann GA, Figueroa JP (2007). Mild chronic hypoxia modifies the fetal
846 sheep neural and cardiovascular responses to repeated umbilical cord occlusion. *Brain Res.* 1176, 18-
847 26.

848

849 Pulgar VM, Hong JK, Jessup JA, Massmann AG, Diz DI & Figueroa JP. (2009). Mild chronic
850 hypoxemia modifies expression of brain stem angiotensin peptide receptors and reflex responses in
851 fetal sheep. *American Journal of Physiology (Regulatory, Integrative and Comparative Physiology)*
852 297, R446-452.

853

854 Reeves JT Daoud FS & Gentry M (1972). Growth of the fetal calf and its arterial pressure blood gases
855 and hematologic data. *J Appl Physiol* 32, 240-244.

856

857 Richardson BS, Carmichael L, Homan J, Patrick JE (1993). Cerebral oxidative metabolism in fetal
858 sheep with prolonged and graded hypoxemia. *J Dev Physiol.* 19(2):77-83.

859

860 Richardson BS, Bocking AD (1998). Metabolic and circulatory adaptations to chronic hypoxia in the
861 fetus. *Comp Biochem Physiol A Mol Integr Physiol* 119(3), 717-23.

862

863 Robinson JS, Kingston EJ, Jones CT & Thorburn GD. (1979). Studies on experimental growth
864 retardation in sheep. The effect of removal of a endometrial caruncles on fetal size and metabolism.
865 *Journal of Developmental Physiology* 1, 379-398.

866

867 Rouwet EV, Tintu AN, Schellings MW, van Bilsen M, Lutgens E, Hofstra L, Slaaf DW, Ramsay G &
868 Le Noble FA. (2002). Hypoxia induces aortic hypertrophic growth, left ventricular dysfunction, and
869 sympathetic hyperinnervation of peripheral arteries in the chick embryo. *Circulation* 105, 2791-2796.

870

871 Rudolph AM (1984). The fetal circulation and its response to stress. *J Dev Physiol* 6(1), 11-9.

872

873 Semenza GL (2004). Hydroxylation of HIF-1: oxygen sensing at the molecular level. *Physiology*
874 (Bethesda) 19, 176-82.

875

876 Sharma SK, Lucitti JL, Nordman C, Tinney JP, Tobita K & Keller BB. (2006). Impact of hypoxia on
877 early chick embryo growth and cardiovascular function. *Pediatric Research* 59, 116-120.

878

879 Soria R, Julian CG, Vargas E, Moore LG, Giussani DA (2013). Graduated effects of high-altitude
880 hypoxia and highland ancestry on birth size. *Pediatr Res* 74(6), 633-8

881 Stein P, White SE, Homan J, Hanson MA, Bocking AD (1999). Altered fetal cardiovascular
882 responses to prolonged hypoxia after sinoaortic denervation. *Am J Physiol.* 276(2 Pt 2):R340-6.
883

884 Supramaniam VG, Jenkin G, Loose J, Wallace EM & Miller SL. (2006). Chronic fetal hypoxia
885 increases activin A concentrations in the late-pregnant sheep. *British Journal of Obstetrics &*
886 *Gynaecology* 113, 102-109.
887

888 Thakor AS, Richter HG, Kane AD, Dunster C, Kelly FJ, Poston L, Giussani DA (2010). Redox
889 modulation of the fetal cardiovascular defence to hypoxaemia. *J Physiol* 588(Pt 21), 4235-47.
890

891 Thakor AS, Allison BJ, Niu Y, Botting KJ, Serón-Ferré M, Herrera EA, Giussani DA (2015).
892 Melatonin modulates the fetal cardiovascular defense response to acute hypoxia. *J Pineal Res.* Apr 22.
893 doi: 10.1111/jpi.12242. [Epub ahead of print].
894

895 Thompson LP (2003). Effects of chronic hypoxia on fetal coronary responses. *High Alt Med Biol.*
896 4(2), 215-24.
897

898 Tintu A, Rouwet E, Verlohren S, Brinkmann J, Ahmad S, Crispi F, van Bilsen M, Carmeliet P, Staff
899 AC, Tjwa M, Cetin I, Gratacos E, Hernandez-Andrade E, Hofstra L, Jacobs M, Lamers WH, Morano
900 I, Safak E, Ahmed A & le Noble F. (2009). Hypoxia induces dilated cardiomyopathy in the chick
901 embryo: mechanism, intervention, and long-term consequences. *PloS One* 4, e5155.
902

903 Tissot van Patot MC, Ebensperger G, Gassmann M, Llanos AJ (2012). The hypoxic placenta. *High*
904 *Alt Med Biol.* 2012 Sep;13(3):176-84.
905

906 Vuilleumier J & Keck E (1989). Fluorometric assay of vitamin C in biological materials using a
907 centrifugal analyser with fluorescence attachment. *J Micronutrient Analysis*, 25-34.

Experimental day	Descending aortic O ₂ content mmol.L ⁻¹		Descending aortic blood glucose mmol.L ⁻¹		Ascending aortic O ₂ content mmol.L ⁻¹		Ascending aortic blood glucose mmol.L ⁻¹		Carotid blood flow ml.min ⁻¹		Femoral blood flow ml.min ⁻¹	
	N	H	N	H	N	H	N	H	N	H	N	H
-3d	2.81±0.08	3.20±0.24	0.89±0.17	0.86±0.03	3.17±0.13	3.90±0.19	0.97±0.26	0.91±0.04	68.8±13.8	69.7±2.4	30.8±4.6	32.0±2.9
-2d	2.93±0.22	3.17±0.19	0.90±0.11	0.89±0.08	3.23±0.18	3.25±0.05	0.83±0.20	0.85±0.05	71.7±10.4	81.2±4.0	29.6±3.8	36.1±3.4
-1d	3.14±0.12	3.30±0.07	0.83±0.15	1.20±0.12	3.17±0.14	3.59±0.07	0.98±0.12	1.17±0.12	72.8±9.1	74.3±5.3	28.5±0.6	36.1±3.4
(-1hr)	2.89±0.44	3.42±0.20	0.72±0.13	0.98±0.11	3.17±0.38	3.65±0.22	0.83±0.07	0.96±0.11	69.7±10.8	81.4±7.1	35.9±0.0	37.3±1.9
(+6hr)	2.89±0.41	1.82±0.24*†	0.78±0.10	1.02±0.07	3.39±0.47	1.91±0.21*†	0.79±0.09	1.04±0.10	68.2±12.3	104.1±7.5*	35.5±0.4	44.3±4.1
(+24hr)	2.93±0.50	1.63±0.31*†	0.76±0.16	0.97±0.08	3.34±0.43	1.89±0.32*†	0.73±0.10	0.98±0.10	64.5±8.9	96.8±9.9	33.1±1.2	47.1±3.2*
d2	2.81±0.19	2.08±0.38*	0.82±0.14	0.92±0.08	3.21±0.15	2.01±0.26*†	0.76±0.11	0.86±0.09	76.9±11.8	90.9±10.7†	35.8±1.1	40.8±3.0*†
d3	3.05±0.17	2.25±0.37*	0.79±0.09	1.03±0.15	3.54±0.15	2.51±0.27*†	0.82±0.10	0.96±0.14	78.2±8.2	86.2±12.1†	33.8±3.0	36.2±1.1†
d4	3.03±0.22	2.17±0.30*†	0.77±0.18	0.98±0.03	3.49±0.19	2.56±0.24*†	0.70±0.15	0.89±0.05	74.8±7.7	104.4±11.7*	36.0±3.6	45.6±3.6†
d5	3.22±0.41	1.89±0.39*†	0.67±0.16	0.84±0.08	3.52±0.20	2.01±0.32*†	0.72±0.12	0.79±0.07	69.3±6.0	96.4±11.6*	35.4±4.3	43.3±1.5
d6	3.01±0.41	2.16±0.35*	0.61±0.09	0.92±0.04	3.45±0.29	2.44±0.38*†	0.73±0.09	0.96±0.06	77.3±7.1	88.2±11.5*	35.9±5.1	38.8±2.3†
d7	2.74±0.25	2.64±0.35*	0.72±0.15	0.89±0.08	3.03±0.10	2.81±0.35	0.73±0.16	0.91±0.11	82.2±10.0	103.7±14.6	38.9±4.8	40.8±1.9
d8	3.20±0.38	1.62±0.17*†	0.82±0.10	0.90±0.11	3.33±0.42	1.79±0.12*†	0.77±0.15	0.92±0.11	81.9±7.8	101.4±7.7*	44.2±1.2	43.2±1.9
d9	2.86±0.09	2.27±0.40*	0.80±0.11	0.78±0.11	3.29±0.16	2.67±0.20*	0.69±0.13	0.84±0.09	93.0±12.7	82.4±11.6*	45.4±3.3*	35.7±1.7
d10	2.73±0.11	2.56±0.54*	0.72±0.15	0.81±0.07	3.40±0.04	2.92±0.61*	0.85±0.16	0.84±0.08	90.2±10.1	94.9±8.3	37.0±1.2*	39.5±1.8
d11	3.11±0.21	2.30±0.16*†	0.62±0.10	0.79±0.04	3.26±0.27	2.69±0.29*	0.80±0.15	0.82±0.07	82.5±5.4	101.3±12.6*	36.2±1.3	39.9±7.2
d12(N)	3.03±0.20	4.40±0.19†	0.69±0.11	0.62±0.04	3.35±0.17	4.58±0.18†	0.86±0.17	0.65±0.05	83.2±10.3	85.3±7.2*	36.8±1.0	29.7±3.7†
d13(N)	2.64±0.17	4.35±0.38†	0.69±0.12	0.80±0.06	2.70±0.12	4.82±0.25	0.66±0.13	0.76±0.03	101.8±16.2*	92.9±9.7*	37.1±2.3	30.1±0.7

Table 1. Variables used to calculate oxygen and glucose delivery in the chronically hypoxic fetus. Values are means ± S.E.M variables required to calculate oxygen and glucose delivery throughout the experimental protocol. Data are shown for fetal ascending and descending arterial oxygen content, blood glucose and flows in normoxic (N) and hypoxic (H) fetuses (n= 6 both groups). Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test).




Figure 1. Isobaric hypoxic chambers and the CamDAS system. Each chamber was equipped with an electronic servo-controlled humidity cool steam injection system to return the appropriate humidity to the inspirate (i). Ambient PO_2 , PCO_2 , humidity and temperature within each chamber were monitored via sensors (ii). For experimental procedures, each chamber had a double transfer port (iii) to internalise material and a manually-operated sliding panel (iv) to bring the ewe into a position where daily sampling of blood could be achieved through glove compartments (v). Each chamber incorporated a drinking bowl on continuous water supply and a rotating food compartment (vi) for determining food intake. A sealed transfer isolation cart could be attached to a side exit (vii) to couple chambers together for cleaning. The camDAS system was contained in a custom-made sheep jacket able to hold the data acquisition system box (ix) in one side pouch and a box containing the Transonic flow probe and pressure connectors (x) in the other. Cables (xi) connected the two boxes together and also to two battery packs able to power the system for 24 hours. Measurements made using the data acquisition were transmitted wirelessly via Bluetooth (xiii) to a laptop kept outside the chamber room (xii) on which it was possible to view continuous recordings of the maternal and fetal cardiovascular data.




Figure 2. Maternal blood gas, acid base and metabolic status. Values are mean±S.E.M. for pregnant sheep undergoing normoxic (O, n=6) or chronic hypoxic (●, n=6) pregnancy. Maternal blood gas values were corrected to 38°C. pH, arterial pH; PaCO₂, arterial CO₂ partial pressure; PaO₂, arterial O₂ partial pressure; Sat[Hb], percentage saturation of haemoglobin; ABE, acid/base excess; Htc, haematocrit; Glucose, blood glucose concentration; Lactate, blood lactate concentration; (N), normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test). For Htc, the comparison of slopes was achieved with the Student's *t* test for unpaired data.




Figure 3. Fetal blood gas, acid base and metabolic status. Values are mean±S.E.M. for fetal sheep undergoing normoxic (O, n=6) or chronic hypoxic (●, n=6) pregnancy. Fetal blood gas values were corrected to 39.5°C. pH, arterial pH; PaCO₂, arterial CO₂ partial pressure; PaO₂, arterial O₂ partial pressure; Sat[Hb], percentage saturation of haemoglobin; ABE, acid/base excess; Htc, haematocrit; Glucose, blood glucose concentration; Lactate, blood lactate concentration; d, days; hr, hour; (N), normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test).




Figure 4. Fetal cardiovascular responses to chronic hypoxia. Values are mean±S.E.M. for the change from baseline in cardiovascular variables in fetal sheep undergoing normoxic (O, n=6, left) or chronic hypoxic (●, n=6, right) pregnancy. CBF, carotid blood flow; FBF, femoral blood flow; d, days; hr, hour; BPM, beats per minute; (N), normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test). For Descending aortic pressure, the two-way ANOVA represents a comparison of slopes. For FBF and CBF, the two-way ANOVA represents a comparison of areas under the curve.




Figure 5. Fetal carotid and femoral arterial oxygen and glucose delivery in the chronically hypoxic fetus. Values are mean±S.E.M. for the change from baseline in oxygen and glucose delivery in the ascending and the descending aorta and the ratio of these values in fetal sheep undergoing normoxic (O, n=6) or chronic hypoxic (●, n=6) pregnancy. d, days; hr, hour; (N), normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test). For the ratio of ascending:descending oxygen delivery, the two way ANOVA represents an analysis of the area under the curve.




Figure 6. Fetal and maternal vitamin C and urate levels in the chronically hypoxic fetus. Values are mean±S.E.M. for the change from baseline in vitamin C and urate in pregnant ewes and fetal sheep undergoing normoxic (O, fetus; □ ewe, n=6) or chronic hypoxic (●, fetus; ■ ewe, n=6) pregnancy. d, days; hr, hour; (N), normoxic recovery. Significant differences (P<0.05): *, differences indicating a significant main effect of time compared with baseline; †, differences indicating a significant main effect of treatment compared with normoxic pregnancy (two way RM ANOVA + Tukey test). For the fetal urate levels the two way ANOVA represents an analysis of the area under the curve.